This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Corcept Therapeutics (CORT) Q4 Earnings Beat Estimates
by Zacks Equity Research
Corcept (CORT) delivered earnings and revenue surprises of 18.18% and 2.32%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Is a Surprise Coming for Corcept (CORT) This Earnings Season?
by Zacks Equity Research
Corcept (CORT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Will Corcept (CORT) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Corcept (CORT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Is Corcept Therapeutics (CORT) a Solid Value Investors Stock?
by Zacks Equity Research
Let's see if Corcept Therapeutics (CORT) stock is a good choice for value-oriented investors right now from multiple angles.
Wall Street Analysts See a 26% Upside in Corcept (CORT): Can the Stock Really Move This High?
by Zacks Equity Research
The mean of analysts' price targets for Corcept (CORT) points to a 25.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
CORT vs. ZTS: Which Stock Is the Better Value Option?
by Zacks Equity Research
CORT vs. ZTS: Which Stock Is the Better Value Option?
Why Is Corcept (CORT) Up 6.6% Since Last Earnings Report?
by Zacks Equity Research
Corcept (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Corcept's (CORT) Q3 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Corcept's (CORT) earnings beat estimates in the third quarter of 2021 while revenues miss the same. The company tightens its revenue guidance for 2021.
Corcept Therapeutics (CORT) Q3 Earnings Top Estimates
by Zacks Equity Research
Corcept (CORT) delivered earnings and revenue surprises of 26.32% and -1.65%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Corcept Therapeutics (CORT) Earnings Expected to Grow: What to Know Ahead of Q3 Release
by Zacks Equity Research
Corcept (CORT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Corcept's (CORT) Q2 Earnings Beat Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Corcept (CORT) beats on both earnings and revenues in the second quarter of 2021. The company maintains the revenue guidance for 2021.
Corcept Therapeutics (CORT) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Corcept (CORT) delivered earnings and revenue surprises of 50.00% and 6.72%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Dr. Reddy's (RDY) Q1 Earnings Decline Y/Y, Sales Increase
by Zacks Equity Research
Dr. Reddy's (RDY) earnings decline while sales grow year over year in first-quarter fiscal 2022.
CORT or ZTS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
CORT vs. ZTS: Which Stock Is the Better Value Option?
Aldeyra's (ALDX) ADX-2191 Gets Orphan Drug Tag for Rare Cancer
by Zacks Equity Research
The FDA grants an Orphan Drug designation to Aldeyra's (ALDX) ADX-2191 for the treatment of primary vitreoretinal lymphoma.
Lilly's (LLY) Protomer Acquisition to Expand Diabetes Pipeline
by Zacks Equity Research
Lilly (LLY), which holds a 14% stake in private biotech company Protomer, acquires the remaining interest in it. The acquisition is set to expand Lilly's diabetes pipeline.
Catalyst (CPRX) Thrives on Firdapse But Overdependence Concerns
by Zacks Equity Research
Catalyst's (CPRX) Firdapse is approved for treating Lambert-Eaton myasthenic syndrome. The drug has seen solid uptake since its launch. Sole dependence on Firdapse for growth remains a concern.
Corcept's (CORT) Lead Drug Korlym Aids Growth Amid Competition
by Zacks Equity Research
Corcept's (CORT) Cushing's syndrome drug, Korlym, is making good progress. Other pipeline candidates are advancing as well. However, sole dependence on Korlym for growth remains an overhang.
Viatris (VTRS) Beats on Q1 Earnings & Sales, Announces Dividend
by Zacks Equity Research
Viatris (VTRS) beats on Q1 earnings while sales surpass expectations. The company announces inaugural quarterly dividend.
Endo's (ENDP) Earnings & Revenues Surpass Estimates in Q1
by Zacks Equity Research
Endo's (ENDP) earnings and sales beat estimates in the first quarter, driven by revived demand.
Corcept's (CORT) Q1 Earnings Miss Estimates, Revenues Fall Y/Y
by Zacks Equity Research
Corcept (CORT) reports wider-than-expected loss in the first quarter of 2021, with its revenues also missing estimates.
Corcept Therapeutics (CORT) Misses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Corcept (CORT) delivered earnings and revenue surprises of -14.29% and -18.53%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Aerie's (AERI) Q1 Loss Wider Than Expected, Revenues Miss
by Zacks Equity Research
Aerie (AERI) incurs a wider loss in the first quarter of 2021 and sales miss expectations.
Jazz Pharma (JAZZ) Q1 Earnings Beat, Sales Miss, Stock Down
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) reports mixed first-quarter 2021 results as earnings beat estimates while sales miss the same. Shares down
Pacira's (PCRX) Q1 Earnings Lag Estimates, Revenues Beat
by Zacks Equity Research
Pacira's (PCRX) earnings in the first quarter of 2021 miss estimates while revenues beat the same. Exparel sales rise year over year.